H. Lundbeck A/S- (HLUYY) Downgraded to “Hold” at Zacks Investment Research
H. Lundbeck A/S- (NASDAQ:HLUYY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “
Separately, Jefferies Group LLC downgraded shares of H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research report on Tuesday, April 11th.
Shares of H. Lundbeck A/S- (NASDAQ:HLUYY) traded up 0.96% during trading on Monday, reaching $57.93. The firm has a market cap of $11.43 billion and a PE ratio of 46.09. H. Lundbeck A/S- has a 52 week low of $31.00 and a 52 week high of $60.78. The company has a 50 day moving average of $53.03 and a 200 day moving average of $46.19.
WARNING: “H. Lundbeck A/S- (HLUYY) Downgraded to “Hold” at Zacks Investment Research” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/07/17/h-lundbeck-as-hluyy-downgraded-to-hold-at-zacks-investment-research.html.
About H. Lundbeck A/S-
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.